权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Delivery Technologies for In Vivo Genome Editing

体内基因组编辑的传递技术

基本信息

批准号：
9805901
负责人：
Elliot Chaikof
金额：
$ 79.68万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-22 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9805901
关键词：
3T3 Cells Alleles Animal Testing Animals Antibodies Base Pairing Binding C57BL/6 Mouse Capsid Capsid Proteins Cells Clinical Trials Collaborations DNA DNA Double Strand Break DNA delivery DNA sequencing Development Endocytosis Engineering Exposure to Flow Cytometry Fluorescence Genetic Diseases Genome Hematopoietic stem cells High-Throughput DNA Sequencing High-Throughput Nucleotide Sequencing Homing In Vitro Individual Injections Kinetics Lipids Liver Luminescent Measurements Macaca mulatta Mediating Methods Mitotic Modification Mus Mutate Nucleic Acids Oncogenic Outcome Patients Point Mutation Process Proteins RNA Reagent Reporter Reporter Genes Reporting Ribonucleoproteins Risk Safety Simian virus 40 Site Somatic Cell Specificity System Target Populations Technology Tissues Transgenic Mice Tropism Viral aptamer base cell type clinical development clinical translation clinically relevant design embryonic stem cell genome editing immunogenicity improved in vivo insertion/deletion mutation large scale production lipid nanoparticle luminescence nanoparticle delivery nonhuman primate novel nuclease nucleocytoplasmic transport particle programs repaired somatic cell gene editing stoichiometry tool uptake whole body imaging

项目摘要

Project Summary New in vivo delivery technologies are urgently needed that enable selective genome editing of somatic cells without the limitations of existing viral delivery systems or lipid nanoparticles. We propose to develop two complementary strategies. First, by tethering Cas9 and base editor ribonucleoproteins (RNPs) to homing moieties, such as antibodies or nucleic acid aptamers, we will develop delivery systems capable of editing a specific population of target cells. As a second approach, we will engineer viral like particles (VLPs) to facilitate efficient, tissue and cell specific delivery of genome editing agents. In the process, we will develop delivery systems that are capable of targeting hematopoietic stem and progenitor cells (HSPCs), among other tissues. To evaluate the efficiency and cell-type specificity of our proposed delivery methods, we will also generate a reporter mouse that quantitatively and sensitively reports genome editing from base editors or programmable nucleases without requiring DNA sequencing. In this proposal, we intend to: (1) Design targeted ribonucleoprotein conjugates that selectively bind, enter, and edit target cells. Cell and tissue selective Cas9 and base editor RNP delivery systems will be designed by tethering genome editing proteins, directly or indirectly, to aptamer and antibody targeting moieties. The kinetics, magnitude, and specificity of RNP endocytosis, endosomal escape, and nuclear transport will be defined and genome editing efficiency and targeting specificity determined in vitro and in vivo. (2) Engineer ribonucleoprotein nanoparticle delivery systems for cell and tissue targeted genome editing. SV40 capsid proteins will be engineered to form viral like particles (VLPs) that are capable of packaging ribonucleoproteins, rather than DNA. The stoichiometry of VLP-RNP delivery systems, which affords optimal cell uptake, endosomal escape, and nuclear transport will be defined. Targeting specificity, as determined by viral capsid tropism will be defined, and genome editing efficiency analyzed in vitro and in vivo. (3) Develop a reporter mouse for facile assessment of targeted genome editing efficiency and cell- and tissue-type specificity. We will optimize a reporter gene to independently detect base editing, end-joining, or homology-directed repair. The reporter will be integrated into the Rosa26 safe harbor locus in C57BL/6 mouse embryonic stem cells to generate transgenic mice. Genome editing outcomes will be evaluated by fluorescence and luminescence measurements and correlated with high throughput DNA sequencing. (4) Demonstrate safe and effective delivery of genome editing agents in non-human primates. The delivery of genome editors to HSPCs and other target tissues will be assessed in rhesus macaques. Both mammalian and non-mammalian systems will be evaluated to optimize large scale production of the genome editor and related RNP delivery components. Targeting specificity and genome editing efficiency, as well as safety will be analyzed in vivo. We anticipate identifying effective delivery systems suitable for clinical trials.

项目总结